ClinicalTrials.gg
TerminatedNCT00637806Updated May 2, 2016Results posted

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

A Phase 3 interventional study of Megestrol acetate concentrated suspension 110 mg/mL and Megestrol acetate concentrated suspension 60 mg/mL in Anorexia, Cachexia and Weight Loss, sponsored by Par Pharmaceutical, Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 3, Interventional, and Treatment

Why this study was terminated
Difficulty finding the required patient population

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Megestrol Acetate in Anorexia — 1 open to participants now, 1 under way, none of them phase 3. Megestrol Acetate · Anorexia.

Enrollment
8th of 10
4 · median 19
Started
2006
with 1 other
Phase 3
6 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
2 of 12
Par Pharmaceutical, Inc.

Among the 12 studies testing Megestrol Acetate in Anorexia, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 7th registered.

Anorexia

163 studies on the registry are indexed under Anorexia; 25 are open to participants now.

Browse Anorexia studies →

Open to participants now

1 of the 12 studies testing Megestrol Acetate in Anorexia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Anorexia studies recruiting now, 6 (50%) set no upper age limit and 6 (50%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Megestrol Acetate in Anorexia, or all of them as a file.
02

Study summary

To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.

03

Conditions studied

  • Anorexia
  • Cachexia
  • Weight Loss

Keywords

  • Megestrol acetate
  • Anorexia
  • Cachexia
  • Cancer
  • Unintended weight loss
  • Body weight
  • Appetite
  • Megace ES
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cancer of multiple types in stage II, III, or IV and not a candidate for chemotherapy; but may have been receiving radiation therapy
  • Fair, poor, or very poor appetite
  • Cancer-associated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months)
  • Weight loss perceived to be associated with diminished appetite
  • Performance score of 0, 1, or 2
  • greater than 3 months
  • Alert and mentally competent to complete study assessments
  • Women of required to use an adequate and reliable method of . women have to have been so for at least 1 year
  • Screening laboratory values must not be (some exceptions per protocol)

Exclusion criteria

Exclusion Criteria:

  • Brain, or head and neck tumors that may interfere with food consumption
  • AIDS-related wasting
  • Radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption
  • Presence of conditions that interfere with oral intake or ability to swallow
  • Absence of normally functioning gut
  • Known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome
  • Intractable or frequent vomiting
  • diarrhea
  • History of thromboembolic events, or on long-term anticoagulation for thromboembolism
  • Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism
  • Poorly controlled hypertension or congestive heart failure
  • Pregnant/lactating females, or planning on becoming pregnant
  • Use of appetite stimulants within past 30 days
  • Use of parenteral nutrition or tube feedings within past 1 week
  • Chronic use of within past 3 months (intermittent short-term use allowed)
  • Current use of illicit substances
  • Allergy, , or other to megestrol acetate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Active comparator
    1

    Megestrol acetate concentrated suspension 110 mg/mL

    Drug: Megestrol acetate concentrated suspension 110 mg/mL

  • Active comparator
    2

    Megestrol acetate concentrated suspension 60 mg/mL

    Drug: Megestrol acetate concentrated suspension 60 mg/mL

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • DrugMegestrol acetate concentrated suspension 110 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

    Also known as: Megace ES

  • DrugMegestrol acetate concentrated suspension 60 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

    Also known as: Megace ES

  • DrugPlacebo

    Placebo oral suspension, 5 mL once daily

06

What researchers measure

Primary outcomes

  1. Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase

    The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value.

    Time frame: 8 weeks

Secondary outcomes

  1. Change in Weight Over the Course of the 8-week Double-blind Phase

    Time frame: Baseline, Week 1, 2, 3, 4, 6, and 8

  2. Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline

    Time frame: Baseline, Week 4 and Week 8

  3. Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale

    Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and 8

07

Results

Posted May 2, 2016

Participant flow

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneDB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboOL MA-CS 550 mg/Day
Started2020
Completed0010
Not completed2010
Withdrew: Study discontinued2010
Extension Phase
Participant flow — Extension Phase
MilestoneDB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboOL MA-CS 550 mg/Day
Started0001
Completed0000
Not completed0001
Withdrew: Study discontinued0001

Outcome measures

PrimaryAverage Daily Caloric Intake Over the Course of the 8-week Double-blind Phase

The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value.

Time frame:
8 weeks

No measurements were reported for this outcome.

SecondaryChange in Weight Over the Course of the 8-week Double-blind Phase
Time frame:
Baseline, Week 1, 2, 3, 4, 6, and 8

No measurements were reported for this outcome.

SecondaryChanges in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline
Time frame:
Baseline, Week 4 and Week 8

No measurements were reported for this outcome.

SecondaryChange in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale

Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6 and 8

No measurements were reported for this outcome.

Adverse events

Collected over Approximately 98 days (from informed consent through 7 days following the last dose of study drug or up until the last protocol-specified study visit, whichever occurred later). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB MA-CS 550 mg/Day—0/2 (0%)1/2 (50%)
DB MA-CS 300 mg/Day———
DB Placebo—1/2 (50%)2/2 (100%)
OL MA-CS 550 mg/Day—1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventDB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboOL MA-CS 550 mg/Day
Accident at homeInjury, poisoning and procedural complications0/2—0/21/1
Rib fractureInjury, poisoning and procedural complications0/2—0/21/1
ConcussionInjury, poisoning and procedural complications0/2—0/21/1
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2—1/20/1
Most frequent other events
Most frequent other events
EventDB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboOL MA-CS 550 mg/Day
InsomniaPsychiatric disorders0/2—1/21/1
Chest painGeneral disorders0/2—1/21/1
VomitingGastrointestinal disorders0/2—1/21/1
ArthralgiaMusculoskeletal and connective tissue disorders0/2—1/20/1
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2—1/20/1
Abdominal painGastrointestinal disorders1/2—0/20/1
NauseaGastrointestinal disorders1/2—0/20/1
FatigueGeneral disorders1/2—0/20/1

Baseline characteristics

All subjects who received at least 1 dose of study medication and who had at least 1 on-therapy safety assessment

Age, Categorical
Age, Categorical(participants)DB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboTotal
<=18 years0—00
Between 18 and 65 years1—01
>=65 years1—23
Gender
Gender(participants)DB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboTotal
Female1—01
Male1—23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(participants)DB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboTotal
Hispanic or Latino0—00
Not Hispanic or Latino2—24
Unknown or Not Reported0—00
Race (NIH/OMB)
Race (NIH/OMB)(participants)DB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboTotal
American Indian or Alaska Native0—00
Asian0—11
Native Hawaiian or Other Pacific Islander0—00
Black or African American0—00
White2—13
More than one race0—00
Unknown or Not Reported0—00
Region of Enrollment
Region of Enrollment(participants)DB MA-CS 550 mg/DayDB MA-CS 300 mg/DayDB PlaceboTotal
United States2—24
08

Study locations

4 sites
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Four Seasons Hospice and Paliative Care
    Flat Rock, North Carolina 28731, United States
  • Wake Forest University
    High Point, North Carolina 27262, United States
  • Summit Oncology Associates, Inc.
    Akron, Ohio 44304, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 9 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
Jun 2006
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Results first posted
May 2, 2016
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00637806
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
Jun 2006
Primary completion
Sep 2006
Completion
Sep 2006
Results posted
May 2, 2016
Last update
May 2, 2016

Study contacts

Lynn D Kramer, MD
study chair · Par Pharmaceutical, Inc.
Janet Bull, MD
principal investigator · Four Seasons Hospice and Paliative Care
Veena Charu, MD
principal investigator · Pacific Cancer Medical Center, Inc.
Bart Frizzell, MD
principal investigator · Wake Forest University, Dept of Radiation Oncology
Mehool Patel, MD
principal investigator · Summit Oncology Associates, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion